Seroatlas · Human Serome Atlas

AKR1B15

Aldo-keto reductase family 1 member B15

Also known as: AK1BF_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: C9JRZ8
Gene: AKR1B15
Ensembl: ENSG00000227471
Chromosome: 7
Canonical length: 316 aa
Protein class: Enzymes, Metabolic proteins, Predicted intracellular proteins
Subcellular location: Plasma membrane,Cytosol

OverviewNCBI Gene

Enables estradiol 17-beta-dehydrogenase [NAD(P)+] activity. Predicted to be involved in estrogen biosynthetic process. Located in cytosol and mitochondrion. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

316 residues, UniProt reviewed canonical sequence.

>C9JRZ8|AKR1B15
     1  MATFVELSTK AKMPIVGLGT WRSLLGKVKE AVKVAIDAEY RHIDCAYFYE NQHEVGEAIQ
    61  EKIQEKAVMR EDLFIVSKVW PTFFERPLVR KAFEKTLKDL KLSYLDVYLI HWPQGFKTGD
   121  DFFPKDDKGN MISGKGTFLD AWEAMEELVD EGLVKALGVS NFNHFQIERL LNKPGLKYKP
   181  VTNQVECHPY LTQEKLIQYC HSKGITVTAY SPLGSPDRPW AKPEDPSLLE DPKIKEIAAK
   241  HKKTTAQVLI RFHIQRNVTV IPKSMTPAHI VENIQVFDFK LSDEEMATIL SFNRNWRAFD
   301  FKEFSHLEDF PFDAEY

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against AKR1B15 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.22
Highest tissue expression: 157 nTPM

Expression across tissuesHPA

Tissue

breast: 157 nTPM
tongue: 18 nTPM
duodenum: 13 nTPM
stomach: 11 nTPM
skeletal muscle: 8.4 nTPM
gallbladder: 4.9 nTPM

Single-cell type

syncytiotrophoblasts: 27 nCPM
myosatellite cells: 8 nCPM
suprabasal keratinocytes: 6.3 nCPM
late spermatids: 5.9 nCPM
thymic myoid cells: 5.4 nCPM
esophageal apical cells: 4.8 nCPM

Immune cell

basophil: 0.2 nTPM
eosinophil: 0.1 nTPM
classical monocyte: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

basal ganglia: 5.3 nTPM
thalamus: 5.3 nTPM
white matter: 5.3 nTPM
midbrain: 4.7 nTPM
hypothalamus: 4.4 nTPM
spinal cord: 4 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about AKR1B15.

Disease | ImmuneIEDB

Conditions an epitope on AKR1B15 was assayed in.

tonsil squamous cell carcinoma T cell

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.93
gnomAD pLI: 0
gnomAD missense Z: -0.93
DepMap mean gene effect: -0.24
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

estrogen biosynthetic process

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads AKR1B15 as an antibody target. Whether an autoantibody or antibody against AKR1B15 could matter depends on whether native AKR1B15 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

AKR1B15 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label AKR1B15 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...